R-006
Risperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C23H27FN4O2
Numero CAS:
Peso molecolare:
410.48
Codice UNSPSC:
41116107
NACRES:
NA.24
Prodotti consigliati
Grado
certified reference material
Forma fisica
liquid
Caratteristiche
Snap-N-Spike®/Snap-N-Shoot®
Confezionamento
ampule of 1 mL
Produttore/marchio commerciale
Cerilliant®
Concentrazione
1.0 mg/mL in methanol
tecniche
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
applicazioni
clinical testing
Formato
single component solution
Temperatura di conservazione
−20°C
Stringa SMILE
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1
InChI
1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
RAPZEAPATHNIPO-UHFFFAOYSA-N
Informazioni sul gene
human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)
Categorie correlate
Descrizione generale
Risperidone, marketed as Risperdal®, Ridal, or Riscalin, is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and irritability in autistic children. This new Certified Snap-N-Spike® Solution is suitable for many LC/MS and GC/MS applications including forensic analysis, clinical toxicology, or urine drug testing.
Applicazioni
- Vascular Syndromes and Neuroleptic Therapy: RisperiDonesolution has been investigated for its role in inducing severe vascular occlusion-like syndromes in rat models. Research highlights its potential implications for understanding drug-induced vascular problems and testing therapies like BPC 157, a gastric pentadecapeptide with promising therapeutic effects (Strbe et al., 2023).
- UHPLC Method Development: RisperiDoneis a focal point in the development of an advanced UHPLC method using the "Method Operable Design Region" (MODR) approach. This method is designed for the assay and purity determination of risperiDonein various formulations, crucial for maintaining stringent quality controls in pharmaceutical manufacturing (Pawar et al., 2022).
- Optimizing Antipsychotic Dose Regimens: Research incorporates risperiDoneto explore Maximum A Posteriori (MAP) Bayesian modelling, merging drug plasma concentrations and dopamine receptor occupancy. This approach aims to customize antipsychotic dosing to enhance therapeutic outcomes in individual patients, emphasizing personalized medicine in psychiatry (Ismail et al., 2022).
- Antioxidant-mediated Drug Degradation: Studies on risperiDonealso cover the formulation aspects, such as its inclusion in poly(ethylene carbonate) systems to control drug degradation through antioxidant mediation. This research is pivotal in developing sustained-release formulations that enhance drug stability and efficacy (Bohr et al., 2020).
- Patient-reported Outcomes in Schizophrenia Treatment: RisperiDonesolution is studied for its effectiveness in treating schizophrenia, particularly assessing patient-reported outcomes in long-term therapy settings. This research helps gauge patient satisfaction and treatment efficacy, which is essential for optimizing mental health therapies (Dhanda et al., 2019).
Note legali
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organi bersaglio
Eyes,Central nervous system
Codice della classe di stoccaggio
3 - Flammable liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
49.5 °F - closed cup
Punto d’infiammabilità (°C)
9.7 °C - closed cup
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
Zhiyun Wei et al.
Journal of clinical psychopharmacology, 33(2), 221-225 (2013-02-21)
Histamine interacts with histamine H4 receptor (HRH4) to impact antipsychotic response. Pharmacogenetic information about this receptor could therefore be useful in developing individualized therapy. The aim of this investigation was to clarify whether polymorphisms at human HRH4 gene alter risperidone
Camilo de la Fuente-Sandoval et al.
JAMA psychiatry, 70(10), 1057-1066 (2013-08-24)
Increased glutamate levels in the right associative striatum have been described in patients during a first episode of psychosis. Whether this increase would persist after effective antipsychotic treatment is unknown. To compare the glutamate levels in antipsychotic-naive patients with first-episode
Helen Blair Simpson et al.
JAMA psychiatry, 70(11), 1190-1199 (2013-09-13)
Obsessive-compulsive disorder (OCD) is one of the world's most disabling illnesses according to the World Health Organization. Serotonin reuptake inhibitors (SRIs) are the only medications approved by the Food and Drug Administration to treat OCD, but few patients achieve minimal
Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
W Victor R Vieweg et al.
Psychopharmacology, 228(4), 515-524 (2013-07-03)
A recent publication asserted that even low-dose risperidone may induce corrected QT (QTc) interval prolongation up to 500 ms without drug-induced IKr blockade. We seek to better understand the complexity of any link between risperidone-induced/associated QTc interval prolongation and torsade de
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.